Clinical evaluation of M43

A novel cancer-associated mucin epitope

Richard Goodgame, Catarina Kiefe, Esme Rose, Fred Sutton, Joseph Brown, Elliot Alpert

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A monoclonal antibody to colon carcinoma mucin was found to react with a colon carcinoma-associated carbohydrate epitope. This antibody was used to develop a quantitative solid phase immunoassay, M43. We prospectively and retrospectively evaluated the assay in patients with and without gastrointestinal carcinoma and compared the sensitivity and specificity with that of carcinoembryonic antigen (CEA) and CA 19-9. One hundred ninety-two patients (181 with no evidence of malignancy) referred for upper or lower gastrointestinal endoscopy were prospectively studied. Sera from 172 patients with histologically confirmed gastrointestinal adenocarcinoma were retrospectively studied. Optimal discrimination cutoffs for M43 (5 units/ml), CEA (5 ng/ml), and CA19-9 (30 units/ml) were determined by receiver operating characteristic curves analysis. M43 was positive in 112 of 151 patients with colorectal carcinoma (sensitivity 74%) and was negative in 167 of 181 patients without carcinoma (specificity 92%). Sensitivity and specificity were 77% and 93% for CEA and 60% and 83% for CA 19-9. Sixty-four % of 73 patients with colorectal carcinoma limited to the bowel wall had a positive M43 with a mean value of 178 units/ml. Eighty-one % of 27 patients with nonhepatic metastasis had a positive M43 with a mean value of 223 units/ml. Eighty-four % of 51 patients with hepatic metastasis had a positive M43 assay with a mean value of 2532 units/ml. Sensitivity in these three groups was 67%, 82%, and 82%, respectively, for CEA and 43%, 68%, and 79%, respectively, for CA 19-9. Of 38 carcinoma patients with a negative CEA, 45% had a positive M43. No correlation between the levels of M43 and CEA in patients with colorectal carcinoma was found. We conclude that M43 is positive in most patients with colorectal carcinoma, even in early stages. As a diagnostic test, its sensitivity and specificity are equivalent to those of CEA. However, the M43 assay is measuring a tumor antigen which is fundamentally different from CEA and which is present in a high percentage of CEA-negative patients.

Original languageEnglish (US)
Pages (from-to)2803-2809
Number of pages7
JournalCancer Research
Volume53
Issue number12
StatePublished - Jun 15 1993
Externally publishedYes

Fingerprint

Mucins
Epitopes
Carcinoembryonic Antigen
Neoplasms
Colorectal Neoplasms
Carcinoma
Sensitivity and Specificity
Colon
Neoplasm Metastasis
Gastrointestinal Endoscopy
Neoplasm Antigens
Immunoassay
Routine Diagnostic Tests
ROC Curve
Adenocarcinoma
Monoclonal Antibodies
Carbohydrates

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Goodgame, R., Kiefe, C., Rose, E., Sutton, F., Brown, J., & Alpert, E. (1993). Clinical evaluation of M43: A novel cancer-associated mucin epitope. Cancer Research, 53(12), 2803-2809.

Clinical evaluation of M43 : A novel cancer-associated mucin epitope. / Goodgame, Richard; Kiefe, Catarina; Rose, Esme; Sutton, Fred; Brown, Joseph; Alpert, Elliot.

In: Cancer Research, Vol. 53, No. 12, 15.06.1993, p. 2803-2809.

Research output: Contribution to journalArticle

Goodgame, R, Kiefe, C, Rose, E, Sutton, F, Brown, J & Alpert, E 1993, 'Clinical evaluation of M43: A novel cancer-associated mucin epitope', Cancer Research, vol. 53, no. 12, pp. 2803-2809.
Goodgame R, Kiefe C, Rose E, Sutton F, Brown J, Alpert E. Clinical evaluation of M43: A novel cancer-associated mucin epitope. Cancer Research. 1993 Jun 15;53(12):2803-2809.
Goodgame, Richard ; Kiefe, Catarina ; Rose, Esme ; Sutton, Fred ; Brown, Joseph ; Alpert, Elliot. / Clinical evaluation of M43 : A novel cancer-associated mucin epitope. In: Cancer Research. 1993 ; Vol. 53, No. 12. pp. 2803-2809.
@article{0936a6876b124ea487a6857c755cd80c,
title = "Clinical evaluation of M43: A novel cancer-associated mucin epitope",
abstract = "A monoclonal antibody to colon carcinoma mucin was found to react with a colon carcinoma-associated carbohydrate epitope. This antibody was used to develop a quantitative solid phase immunoassay, M43. We prospectively and retrospectively evaluated the assay in patients with and without gastrointestinal carcinoma and compared the sensitivity and specificity with that of carcinoembryonic antigen (CEA) and CA 19-9. One hundred ninety-two patients (181 with no evidence of malignancy) referred for upper or lower gastrointestinal endoscopy were prospectively studied. Sera from 172 patients with histologically confirmed gastrointestinal adenocarcinoma were retrospectively studied. Optimal discrimination cutoffs for M43 (5 units/ml), CEA (5 ng/ml), and CA19-9 (30 units/ml) were determined by receiver operating characteristic curves analysis. M43 was positive in 112 of 151 patients with colorectal carcinoma (sensitivity 74{\%}) and was negative in 167 of 181 patients without carcinoma (specificity 92{\%}). Sensitivity and specificity were 77{\%} and 93{\%} for CEA and 60{\%} and 83{\%} for CA 19-9. Sixty-four {\%} of 73 patients with colorectal carcinoma limited to the bowel wall had a positive M43 with a mean value of 178 units/ml. Eighty-one {\%} of 27 patients with nonhepatic metastasis had a positive M43 with a mean value of 223 units/ml. Eighty-four {\%} of 51 patients with hepatic metastasis had a positive M43 assay with a mean value of 2532 units/ml. Sensitivity in these three groups was 67{\%}, 82{\%}, and 82{\%}, respectively, for CEA and 43{\%}, 68{\%}, and 79{\%}, respectively, for CA 19-9. Of 38 carcinoma patients with a negative CEA, 45{\%} had a positive M43. No correlation between the levels of M43 and CEA in patients with colorectal carcinoma was found. We conclude that M43 is positive in most patients with colorectal carcinoma, even in early stages. As a diagnostic test, its sensitivity and specificity are equivalent to those of CEA. However, the M43 assay is measuring a tumor antigen which is fundamentally different from CEA and which is present in a high percentage of CEA-negative patients.",
author = "Richard Goodgame and Catarina Kiefe and Esme Rose and Fred Sutton and Joseph Brown and Elliot Alpert",
year = "1993",
month = "6",
day = "15",
language = "English (US)",
volume = "53",
pages = "2803--2809",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Clinical evaluation of M43

T2 - A novel cancer-associated mucin epitope

AU - Goodgame, Richard

AU - Kiefe, Catarina

AU - Rose, Esme

AU - Sutton, Fred

AU - Brown, Joseph

AU - Alpert, Elliot

PY - 1993/6/15

Y1 - 1993/6/15

N2 - A monoclonal antibody to colon carcinoma mucin was found to react with a colon carcinoma-associated carbohydrate epitope. This antibody was used to develop a quantitative solid phase immunoassay, M43. We prospectively and retrospectively evaluated the assay in patients with and without gastrointestinal carcinoma and compared the sensitivity and specificity with that of carcinoembryonic antigen (CEA) and CA 19-9. One hundred ninety-two patients (181 with no evidence of malignancy) referred for upper or lower gastrointestinal endoscopy were prospectively studied. Sera from 172 patients with histologically confirmed gastrointestinal adenocarcinoma were retrospectively studied. Optimal discrimination cutoffs for M43 (5 units/ml), CEA (5 ng/ml), and CA19-9 (30 units/ml) were determined by receiver operating characteristic curves analysis. M43 was positive in 112 of 151 patients with colorectal carcinoma (sensitivity 74%) and was negative in 167 of 181 patients without carcinoma (specificity 92%). Sensitivity and specificity were 77% and 93% for CEA and 60% and 83% for CA 19-9. Sixty-four % of 73 patients with colorectal carcinoma limited to the bowel wall had a positive M43 with a mean value of 178 units/ml. Eighty-one % of 27 patients with nonhepatic metastasis had a positive M43 with a mean value of 223 units/ml. Eighty-four % of 51 patients with hepatic metastasis had a positive M43 assay with a mean value of 2532 units/ml. Sensitivity in these three groups was 67%, 82%, and 82%, respectively, for CEA and 43%, 68%, and 79%, respectively, for CA 19-9. Of 38 carcinoma patients with a negative CEA, 45% had a positive M43. No correlation between the levels of M43 and CEA in patients with colorectal carcinoma was found. We conclude that M43 is positive in most patients with colorectal carcinoma, even in early stages. As a diagnostic test, its sensitivity and specificity are equivalent to those of CEA. However, the M43 assay is measuring a tumor antigen which is fundamentally different from CEA and which is present in a high percentage of CEA-negative patients.

AB - A monoclonal antibody to colon carcinoma mucin was found to react with a colon carcinoma-associated carbohydrate epitope. This antibody was used to develop a quantitative solid phase immunoassay, M43. We prospectively and retrospectively evaluated the assay in patients with and without gastrointestinal carcinoma and compared the sensitivity and specificity with that of carcinoembryonic antigen (CEA) and CA 19-9. One hundred ninety-two patients (181 with no evidence of malignancy) referred for upper or lower gastrointestinal endoscopy were prospectively studied. Sera from 172 patients with histologically confirmed gastrointestinal adenocarcinoma were retrospectively studied. Optimal discrimination cutoffs for M43 (5 units/ml), CEA (5 ng/ml), and CA19-9 (30 units/ml) were determined by receiver operating characteristic curves analysis. M43 was positive in 112 of 151 patients with colorectal carcinoma (sensitivity 74%) and was negative in 167 of 181 patients without carcinoma (specificity 92%). Sensitivity and specificity were 77% and 93% for CEA and 60% and 83% for CA 19-9. Sixty-four % of 73 patients with colorectal carcinoma limited to the bowel wall had a positive M43 with a mean value of 178 units/ml. Eighty-one % of 27 patients with nonhepatic metastasis had a positive M43 with a mean value of 223 units/ml. Eighty-four % of 51 patients with hepatic metastasis had a positive M43 assay with a mean value of 2532 units/ml. Sensitivity in these three groups was 67%, 82%, and 82%, respectively, for CEA and 43%, 68%, and 79%, respectively, for CA 19-9. Of 38 carcinoma patients with a negative CEA, 45% had a positive M43. No correlation between the levels of M43 and CEA in patients with colorectal carcinoma was found. We conclude that M43 is positive in most patients with colorectal carcinoma, even in early stages. As a diagnostic test, its sensitivity and specificity are equivalent to those of CEA. However, the M43 assay is measuring a tumor antigen which is fundamentally different from CEA and which is present in a high percentage of CEA-negative patients.

UR - http://www.scopus.com/inward/record.url?scp=0027191498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027191498&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 2803

EP - 2809

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 12

ER -